NAD Finds Drug Claim Supported in Physician-Directed Messaging But Not in Consumer-Directed Ads

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

NAD Finds Drug Claim Supported in Physician-Directed Messaging But Not in Consumer-Directed Ads

J.W. Schomisch

January 29, 2023 at 12:20 PM EST

The National Advertising Division (NAD) determined that while Novartis Pharmaceutical provided a reasonable basis for survival benefit claims for its Kisqali breast cancer treatment drug in messaging to health care professionals (HCPs), it did not provide such a basis in consumer-directed ads. NAD recommended the claim in consumer-facing advertising, along with several implie... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

NAD Finds Drug Claim Supported in Physician-Directed Messaging But Not in Consumer-Directed Ads

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT